Market capitalization | $959.24m |
Enterprise Value | $609.31m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 344.24 |
P/S ratio (TTM) P/S ratio | 541.94 |
P/B ratio (TTM) P/B ratio | 2.29 |
Revenue growth (TTM) Revenue growth | 20.97% |
Revenue (TTM) Revenue | $1.77m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
10 Analysts have issued a Praxis Precision Medicines Inc forecast:
10 Analysts have issued a Praxis Precision Medicines Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 1.77 1.77 |
21%
21%
|
|
Gross Profit | 1.12 1.12 |
348%
348%
|
|
EBITDA | -132 -132 |
16%
16%
|
EBIT (Operating Income) EBIT | -133 -133 |
16%
16%
|
Net Profit | -124 -124 |
21%
21%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Praxis Precision Medicines, Inc. is a clinical-stage genetic neuroscience company that develops therapies for patients and families affected by complex and debilitating brain disorders. The company was founded by Kiran Reddy, David Goldstein and Steven Petrou on September 22, 2015 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Marcio Souza |
Employees | 82 |
Founded | 2015 |
Website | www.praxismedicines.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.